Skip to main content

Table 3 Univariate analysis of MSHFS in patients undergoing PLD chemotherapy

From: Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Factor

 

NMHFS(n = 255)

MSHFS(n = 206)

P

Age

 

51.10 ± 9.94

51.17 ± 9.10

0.936

BMI

 

23.44, 21.61–25.71

24.154, 22.21–26.84

0.028*

PLD dose intensity

 

30.18, 26.79–32.20

32.47, 30.50–35.71

<0.001**

Baseline ALT

 

15, 11–19

16, 12–23

0.012*

Baseline AST

 

19, 17–22

20, 12–24

0.023*

Baseline GGT

 

18, 14–24

21, 14–28

0.101

Baseline TBIL

 

12.600, 10–16.1

13.400, 10–16.85

0.297

Baseline MONO

 

0.360, 0.30–0.45

0.400, 0.32–0.46

0.058

Baseline NLR

 

1.800, 1.36–2.45

1.655, 1.31–2.28

0.231

Baseline PLR

 

133.000, 109–170

129.000, 106–171

0.890

Baseline CA153

8.800, 7–12.6

10.000, 6.93–15.0

0.106

Baseline CEA

1.600, 1–2.3

1.700, 1–2.67

0.345

ECOG score

   

0.264

0

251 (98.4)

205 (99.5)

 

1

4 (1.6)

1 (0.5)

 

Hypertension disease

   

0.778

No

231 (90.6)

185 (89.8)

 

Yes

24 (9.4)

21 (10.2)

 

Diabetes

   

0.051

No

232 (91.0)

197 (95.6)

 

Yes

23 (9.0)

9 (4.4)

 

Cholecystitis

   

0.113

No

245 (96.1)

191 (92.7)

 

Yes

10 (3.9)

15 (7.3)

 

History of gallstones

   

0.003**

No

250 (98.0)

190 (92.2)

 

Yes

5 (2.0)

16 (7.8)

 

Peripheral blood circulation

   

<0.001**

Poor

88 (34.5)

34 (16.5)

 

Good

167 (65.5)

171 (83.5)

 

Sweat excretion

   

<0.001**

Normal

227 (89.0)

151 (73.3)

 

Excessive

28 (11.0)

55 (26.7)

 

Allergy or not

   

0.905

No

242 (94.9)

196 (95.1)

 

Yes

13 (5.1)

10 (4.9)

 

Viral hepatitis

   

0.750

No

237 (92.9)

193 (93.7)

 

Yes

18 (7.1)

13 (6.3)

 

With or without tumor

   

0.040*

No

194 (76.1)

139 (67.5)

 

Yes

61 (23.9)

67 (32.5)

 

Ki-67

   

0.921

Low

88 (34.5)

72 (34. 9)

 

High

167 (65.5)

134 (65.1)

 

ER

   

0.406

Negative

81 (31.8)

73 (35.4)

 

Positive

174 (68.2)

133 (64.6)

 

PR

   

0.061

Negative

98 (38.4)

97 (47.1)

 

Positive

157 (61.6)

109 (52.9)

 

HER2

   

0.001**

Negative

208 (81.4)

141 (68.4)

 

Positive

47 (18.4)

65 (31.6)

 
  1. * p < 0.05 ** p < 0.01
  2. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG eastern cooperative oncology group, ER estrogen receptor, GGT γ-glutamyl transpeptidase, HER2 human epidermalgrowth factor receptor-2, Ki-67 antigen identified by monoclonal antibody Ki-67, MSHFS moderate to severe hand-foot syndrome, MONO monocytes, NLR neutrophil-lymphocyte ratio, NMHFS none and mild hand-foot syndrome, PLR platelet-lymphocyte ratio, PR progesterone receptor, TBIL total bilirubin
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us